Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 16/20 | 0.54 |
| ▸ | WNT3 | P56703 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638257 | 0.85 | SFRP1 (0.54) | SFRP1WNT3MEN1KMT2ACA1 | |
| SCHEMBL6101508 | 0.83 | SFRP1 (0.52) | SFRP1WNT3 | |
| SCHEMBL4618246 | 0.83 | SFRP1 (0.67) | SFRP1WNT3 | |
| SCHEMBL4639128 | 0.82 | L3MBTL1 (0.50) | SFRP1WNT3MEN1KMT2ACA1 | |
| SCHEMBL4617854 | 0.80 | SFRP1 (0.60) | SFRP1WNT3 | |
| SCHEMBL4618892 | 0.80 | SFRP1 (0.72) | SFRP1WNT3 | |
| SCHEMBL4637122 | 0.79 | PSEN1 (0.48) | SFRP1WNT3MEN1KMT2APSEN1 | |
| SCHEMBL4638753 | 0.79 | PSEN1 (0.50) | SFRP1WNT3MEN1KMT2APSEN1 | |
| SCHEMBL4618210 | 0.79 | SFRP1 (0.50) | SFRP1WNT3 | |
| SCHEMBL6102183 | 0.79 | SFRP1 (0.52) | SFRP1WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | SFRP1 1/4885WNT3 346/4885MEN1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.